San Diego-based R&D firm signs a research agreement with Otsu, Japan-based Takara Shuzo Co., Cytel announces June 2. The agreement calls for the two firms to develop Cytel's Theradigm technology for "a non-viral, infectious disease target." Takara will buy a $3 mil. equity stake in Cytel as part of the agreement. In addition, the firms have signed a letter of intent to develop Cytel's ex vivo cellular therapy for treatment of cancers...
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth